Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tianyin Receives SFDA Approval for Statin

publication date: Jul 31, 2008

Tianyin Pharmaceutical, Co. was given SFDA approval for a generic version of a statin drug, simvastatin tablets. Simvastatin was developed by Merck, which markets the drug as Zocor. The US patent for the drug expired in 2006. Simvastatin is used to control hypercholesterolemia and treat coronary heart diseases, the only statin approved by the SFDA for these conditions. Tianyin has the ability to produce $2 million of the drug annually. More details...

Stock Symbols: (OTCBB: TYNP) (NYSE: MRK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here